Comparative Pharmacology
Head-to-head clinical analysis: MUPIROCIN versus TINDAMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MUPIROCIN versus TINDAMAX.
MUPIROCIN vs TINDAMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, inhibiting protein synthesis.
Tindamax (tinidazole) is a nitroimidazole antibiotic that enters bacterial and protozoal cells, where the nitro group is reduced by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It exhibits activity against anaerobic bacteria and protozoa.
Apply a small amount of 2% ointment or cream to affected area three times daily for 5 to 14 days.
100 mg intravenously every 8 hours over 60 minutes.
None Documented
None Documented
Intravenous: ~30 min (0.5 h). Topical: systemically absorbed amount negligible, local half-life not defined.
Clinical Note
moderateMupirocin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mupirocin."
Terminal elimination half-life is 4-6 hours; prolonged to 10-12 hours in severe renal impairment (CrCl <30 mL/min).
Renal: <1% unchanged (topical); hepatic metabolism to monic acid, eliminated renally and fecally. After IV administration, 60-70% renal, 20-30% fecal/biliary.
Primarily renal excretion (70-80% as unchanged drug) with 10-15% fecal elimination via biliary secretion.
Category A/B
Category C
Antibiotic
Antibiotic